References
- Ramsay AG, Gribben JG. Immune dysfunction in chronic lymphocytic leukemia T cells and lenalidomide as an immunomodulatory drug. Haematologica 2009;94:1198–1202.
- Chanan-Khan AA, Cheson BD. Lenalidomide for the treatment of B-cell malignancies. J Clin Oncol 2008;26:1544–1552.
- Quach H, Ritchie D, Stewart AK, . Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma. Leukemia 2010;24:22–32.
- Chanan-Khan A, Porter CW. Immunomodulating drugs for chronic lymphocytic and leukemia. Lancet Oncol 2006;7:480–488.
- Wan YY. Regulatory T cells: immune suppression and beyond. Cell Mol Immunol 2010;7:204–210.
- Galustian C, Meyer B, Labarthe MC, . The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells. Cancer Immunol Immunother 2009;58: 1033–1045.
- Idler I, Giannopoulos K, Zenz T, . Lenalidomide treatment of chronic lymphocytic leukaemia patients reduces regulatory T cells and induces Th17 T helper cells. Br J Haematol 2010;148:948–950.
- Lee BN, Gao H, Cohen EN, . Treatment with lenalidomide modulates T-cell immunophenotype and cytokine production in patients with chronic lymphocytic leukemia. Cancer 2011;117: 3999–4008.
- Dimopoulos M, Spencer A, Attal M, ; Multiple Myeloma (010) Study Investigators. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 2007;357:2123–2132.
- Minnema MC, van der Veer MS, Aarts T, . Lenalidomide alone or in combination with dexamethasone is highly effective in patients with relapsed multiple myeloma following allogeneic stem cell transplantation and increases the frequency of CD4+ Foxp3+ T cells. Leukemia 2009;23:605–607.
- Raja KRM, Kovarova L, Hajek R. Induction by lenalidomide and dexamethasone combination increases regulatory cells of patients with previously untreated multiple myeloma. Leuk Lymphoma 2012;53: 1406–1408.
- O’Shea JJ, Paul WE. Mechanisms underlying lineage commitment and plasticity of helper CD4+ T cells. Science 2010;327:1098–1102.
- Bopp T, Becker C, Klein M, . Cyclic adenosine monophosphate is a key component of regulatory T cell-mediated suppression. J Exp Med 2007;204:1303–1310.